Search company, investor...

Stage

Asset Sale

Total Raised

$46.11M

Investors Count

19

Deal Terms

1

Portfolio Exits

1

Investments

3

Funding, Valuation & Revenue

6 Fundings

Endocare has raised $46.11M over 6 rounds.

Endocare's latest funding round was a Acquired for on June 10, 2019.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

6/10/2019

Acquired

$99M

0

FY undefined

1

5/11/2007

Unattributed VC - IV

$99M

$99M

0

FY undefined

0

3/9/2005

Unattributed VC - III

$99M

$99M

0

FY undefined

0

5/12/2000

Unattributed VC - II

$99M

$99M

0

FY undefined

0

4/21/1998

Unattributed VC

$99M

$99M

0

FY undefined

0

Date

6/10/2019

5/11/2007

3/9/2005

5/12/2000

4/21/1998

Round

Acquired

Unattributed VC - IV

Unattributed VC - III

Unattributed VC - II

Unattributed VC

Amount

$99M

$99M

$99M

$99M

Investors

Valuation

$99M

$99M

$99M

$99M

$99M

Revenue

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

Sources

1

0

0

0

0

You're one click away from the most comprehensive, unmatched analyst expertise in tech, in-depth private company data and a platform that brings it all together.
Click Now. Join a live demo
Join a demo
CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo

Endocare Deal Terms

1 Deal Term

Endocare's deal structure is available for 1 funding round, including their Series A from January 01, 1997.

Round

Series A

Funding Date

$99M

Pre-Money Valuation

Post-Money Valuation

Amount Raised

$99M

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

$99M

Board Voting

$99M

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Series A

$99M

$99M

$99M

$99M

Endocare Investors

19 Investors

Endocare has 19 investors. Varian Medical Systems invested in Endocare's Acquired funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

6/10/2019

6/10/2019

1
Acquired

Corporation

California

5/11/2007

5/11/2007

1
Unattributed VC - IV

Private Equity

Washington

3/9/2005

3/9/2005

SRB Management
1
Unattributed VC - III

Hedge Fund

Texas

00/00/0000

00/00/0000

Haimovitch Medical Technology Consultants

Subscribe to see more

Corporation

California

00/00/0000

00/00/0000

Public Employee Retirement System of Idaho

Subscribe to see more

Government

Idaho

First funding

6/10/2019

5/11/2007

3/9/2005

00/00/0000

00/00/0000

Last Funding

6/10/2019

5/11/2007

3/9/2005

00/00/0000

00/00/0000

Investor

SRB Management

Haimovitch Medical Technology Consultants

Public Employee Retirement System of Idaho

Rounds

1
Acquired
1
Unattributed VC - IV
1
Unattributed VC - III

Subscribe to see more

Subscribe to see more

Board Seats

Type

Corporation

Private Equity

Hedge Fund

Corporation

Government

Location

California

Washington

Texas

California

Idaho

Endocare Investments

3 Investments

Endocare has made 3 investments. Their latest investment was in Synendos Therapeutics as part of their Grant on April 20, 2021.

CBI Logo

Endocare Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

4/20/2021

Grant

Synendos Therapeutics

Yes

2

4/10/2006

Series B

Subscribe to see more

Subscribe to see more

0

11/17/1999

Unattributed VC

Subscribe to see more

$99M

Subscribe to see more

0

Date

4/20/2021

4/10/2006

11/17/1999

Round

Grant

Series B

Unattributed VC

Company

Synendos Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

0

0

Endocare Portfolio Exits

1 Portfolio Exit

Endocare has 1 portfolio exit. Their latest portfolio exit was Sanarus on July 10, 2009.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

7/10/2009

Asset Sale

$99M

Date

7/10/2009

Exit

Asset Sale

Companies

Valuation

$99M

Acquirer

Sources

CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo

Compare Endocare to Competitors

ReproCELL Logo
ReproCELL

REPROCELL is a company focused on supporting stem cell research and preclinical drug development within the biotechnology sector. The company offers a range of services including stem cell research, drug discovery, analytical services, gene editing, precision medicine, and clinical laboratory services, as well as products such as stem cell reagents, cells, and 3D cell culture systems. REPROCELL's clientele primarily consists of research institutions and companies in the regenerative medicine and pharmaceutical industries. It was founded in 2003 and is based in Yokohama, Japan.

Stemina Biomarker Discovery Logo
Stemina Biomarker Discovery

Stemina Biomarker Discovery is a developer of molecular biomarkers designed to perform diagnosis and treat neurological disorders, including autism spectrum disorders. It offers the discovery, development, and commercialization of molecular biomarkers for drug safety and human health. It provides compound screening and diagnostic development for the pharmaceutical and biotechnology industries. The company was founded in 2006 and is based in Madison, Wisconsin.

CoImmune Logo
CoImmune

CoImmune is a company that focuses on the development and manufacture of cell-based therapeutics, operating within the healthcare and biotechnology sectors. The company's main offerings include treatments for unmet medical needs such as cancer, autoimmune, and inflammatory diseases. It was founded in 1997 and is based in Durham, North Carolina. CoImmune operates as a subsidiary of Genexine and SCM Lifescience.

E
Esperance Pharmaceuticals

Esperance Pharmaceuticals develops targeted anticancer drugs that selectively kill cancer cells without harming normal cells.

H
Humanetics

Humanetics is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and well-being in markets with urgent and unmet needs. It has a focus on radiation modulators for oncology, medical imaging, and medical countermeasure uses. The company develops BIO 300, a selective modulator of inflammation, cell cycle arrest, and DNA damage repair. Humanetics was founded in 1988 and is based in Minneapolis, Minnesota.

K
Keystone Nano

Keystone Nano seeks to improve human health by creating new ways to diagnose and treat human diseases and improve the quality of life. Keystone Nano partners with healthcare companies to the development and speed the market launch of nano-enabled therapeutics to seek/treat/image a variety of conditions.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.